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Abstract: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of 
the gastrointestinal tract. Surgery with complete removal of the tumor is the primary treatment 
for resectable GIST and the only chance of cure. However, recurrence after surgery is com-
mon. The 2 main prognostic factors are the mitotic activity and the size of the tumor. Tumor 
rupture is also a risk factor for postoperative recurrence, and extra care should be taken while 
manipulating this soft and friable tumor. Imatinib mesylate (IM, Gleevec®, Novartis, Basel, 
Switzerland) is a tyrosine kinase inhibitor and was first studied in the palliative setting for 
metastatic GIST patients in the year 2000. It is now the cornerstone of metastatic GIST treat-
ment. IM also plays an important role as an adjuvant treatment for resectable GIST and has 
been shown to increase the recurrence-free survival in phase III studies. However, some points 
remain to be clarified. Notably, the ideal duration of adjuvant IM after surgery is still unclear. It 
is also difficult to determine the exact place of surgery in metastatic or recurrent GIST patients 
in the IM era. A multidisciplinary approach is, therefore, mandatory to offer GIST patients the 
best treatment available.
Keywords: Gleevec, adjuvant, neoadjuvant, metastasis, sunitinib
Introduction
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of 
the gastrointestinal tract. For years, the only effective treatment available was surgery. 
Although surgery has a high rate of cure for low-risk GIST, it is seldom curative for 
high-risk tumors since the postoperative recurrence rate for GIST with high-risk 
features is usually high. In 1998, Hirota et al demonstrated the central role of a gain-
of-function mutation of the kit gene in this disease process.1 This proto-oncogene 
encodes a transmembrane receptor, CD117. This discovery has led to a revolution in 
the treatment of this disease: the introduction of imatinib mesylate (IM, Gleevec®, 
Novartis, Basel, Switzerland). This molecular-targeted agent, initially developed to 
treat chronic myeloid leukemia, is an inhibitor of multiple receptor tyrosine kinases, 
including the receptor CD117. In the year 2000, IM was first used as a salvage therapy 
in a patient with metastatic GIST who had failed multiple lines of treatment. An 
impressive response was observed with reduction in tumor volume and normalization 
of 18F-fludeoxyglucose (FDG) activity on positron emission tomography (PET).2 This 
success led to the initiation of clinical trials to further evaluate the efficacy of IM in 
GIST treatment.
IM is now a cornerstone in the treatment of GISTs. In this review, we provide a sum-
mary of the initial experience in GIST management in the pre-IM era. The mechanism Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
454
Deshaies et al
of action, pharmacology, safety profile, tolerability, and 
efficacy in clinical studies of IM are also discussed. Finally, 
based on the current data, the role of surgery in conjunction 
with molecular treatment is investigated.
GIST epidemiology  
and pathophysiology
GISTs arise from the interstitial cells of Cajal. The literature 
before the year 2000 on GIST incidence is unreliable because 
this tumor was often misclassified as a smooth muscle tumor 
or other mesenchymal tumor.3 In a population-based study 
conducted in western Sweden, with in-depth pathological and 
histological reviews, the annual incidence of GIST was found 
to be 14.5 cases per million. By extrapolating this number, 
we can estimate that about 3,000–5,000 new cases of GIST 
are probably diagnosed each year in the United States.4
GIST occurs mostly in the stomach (60%–65%) or small 
intestine (25%–35%) but can arise anywhere along the gas-
trointestinal tract.4–7 It is mostly a rare sporadic tumor seen 
in older adults (median age 55–60 years). Familial GIST is 
rare but can be seen in patients with neurofibromatosis type I 
(multiple small intestinal tumors) or Carney’s triad (gastric 
epithelioid GIST, pulmonary chondroma, and extra-adrenal 
paraganglioma). Histologically, 95% of GISTs express the 
transmembrane receptor CD117, which is the main immu-
nohistological marker.5 In tumors lacking a kit mutation, 
approximately 35% have a gain-of-function mutation of 
the platelet-derived growth factor receptor alpha, a related 
tyrosine kinase receptor.8 This mutation is nearly exclusive 
for gastric CD117-negative GISTs.
The clinical behavior of GISTs can vary from a benign to a 
highly aggressive course. The 2 main prognostic factors are the 
mitotic activity and the size of the tumor. More than 5 mitoses 
per 50 high-power fields (HPF) and size greater than 10 cm 
are almost uniformly identified as factors associated with poor 
outcomes after surgery.4,6,9,10 Other factors such as nongastric 
primary tumor location, exon 9 mutation, or “wild type” kit 
also appear to be deleterious prognostic factors.9,11–13
General management
For primary GISTs, only complete surgical resection offers 
a possibility of cure. The initial patient evaluation should 
include a computed tomography (CT) scan of the abdomen 
and pelvis and chest imaging. A PET scan and an endoscopic 
ultrasound can sometimes be included. A biopsy is not man-
datory before surgery, except if neoadjuvant treatment is con-
sidered or if the differential diagnosis includes lymphoma. 
If a biopsy is required, the endoscopic route is preferred to 
decrease the risk of tumor seeding. The main goal of surgery 
is to remove the tumor with negative margins. A 2-cm margin 
should be sought. A regional lymphadenectomy is generally 
not required since GIST rarely (,5%) metastasizes to lymph 
nodes.7,14,15 GIST rarely invades other organs and can usually 
be lifted away from surrounding structures. When this is not 
the case, involved organs should be resected en bloc with the 
specimen. Extra care should be taken while manipulating 
the tumor because GISTs are soft and fragile in nature, and 
intraperitoneal rupture or bleeding is associated with high 
risk of postoperative recurrence.9,16
IM is the cornerstone of metastatic GIST treatment. 
Recurrent GIST should be considered as an equivalent of 
metastatic tumor. The usual starting dose of IM is 400 mg 
daily.16 This treatment is associated with a good disease con-
trol rate, but complete response rate is low. As demonstrated 
in 2 phase III studies, the complete response rate was 5%, 
while the partial response rate reached between 40% and 
45%. Approximately, 25%–32% of patients experienced 
stable disease.17,18 If no major toxicity occurs, IM should 
be continued until disease progression. In the setting of 
disease progression, a dose escalation should be considered. 
When the tumor develops resistance to IM, sunitinib malate 
(SM, Sutent®, Pfizer, New York, NY, USA) is an effective 
second-line therapy.19 The integration of surgery in meta-
static disease needs to be carefully outlined in the context of 
medical therapy. Nonetheless, data to guide surgical decision 
making, such as timing for intervention, are very limited.
Surgery in the pre-IM era
Historically, surgery was the only effective treatment avail-
able for GISTs. However, the risk of postoperative recurrence 
was fairly high in tumors with high-risk features. Pierie et al 
demonstrated a 5-year overall survival (OS) of 42% in GIST 
patients with complete gross resection compared with 9% if 
the excision was incomplete.14 DeMatteo confirmed a simi-
lar 5-year disease-specific survival of 35% in 200 patients 
who had surgical resection for primary or metastatic GIST.7 
In the population-based Swedish study presented earlier, 
recurrences were in 3 out of 169 patients with low- or 
intermediate-risk GIST and in 35 out of 53 patients with 
high- or very high-risk GIST.10
The above studies dealt with the outcomes after surgery 
for primary or recurrent GIST. Rutkowski et al addressed 
the question of recurrence after primary tumor resection 
only, demonstrating a 5-year disease-free survival (DFS) of 
37.8% in patients with resected primary GISTs. As shown in 
the multivariate analysis, more than 5 mitoses per 50 HPF, Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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tumor size greater than 5 cm, nongastric primary location, 
male sex, and R1 resection or tumor rupture were associated 
with adverse outcomes. Patients with low-risk GIST reached 
a 5-year DFS of 96%, whereas those with intermediate- or 
high-risk tumors frequently had much lower DFS, 54% and 
20%, respectively.9 A study on resected metastatic-only GIST 
patients demonstrated a median survival of 19 months and a 
5-year OS of 25%.20
The pre-IM era literature clearly demonstrates an elevated 
risk of recurrence in patients presenting with intermediate- or 
high-risk tumors and metastatic disease treated by surgery 
only. It is clear that surgery alone is not sufficient to provide 
long-term survival for a vast number of GIST patients.
The IM era
The first studies on IM were conducted for metastatic GIST 
patients in the beginning of the year 2000. The initial phase 
II studies demonstrated a good tolerability and an encourag-
ing response. Although complete response was low, partial 
response rate of approximately 54%–67% was reached. In 
addition, 18%–28% of the patients had stable disease.21–23 
Thus, it can be concluded that more than 80% of patients on 
IM therapy would have clinical benefit.
The efficacy of higher dose of IM was assessed in 2 phase 
III studies. In the North American Sarcoma Intergroup S0033 
trial, 746 patients were treated with either 400 mg daily dose 
(standard dose) or 800 mg daily dose of IM. No significant 
difference in progression-free survival was detected between 
the two doses used (18 months in 400 mg and 20 months 
in 800 mg group). Median OS was similar in both groups, 
with 55 months in the standard dose arm and 51 months 
in the higher dose arm.18 In the European Organisation for 
Research and Treatment of Cancer (EORTC) and Australian 
trial, a favorable DFS was documented in patients treated 
with the 800 mg daily dose of IM. However, treatment inter-
ruption and dose reduction were more frequent.17 Subgroup 
analysis demonstrated the feasibility, safety, and efficacy of 
dose escalation upon disease progression.24 Interestingly, 
one subgroup analysis for each trial has also demonstrated 
that patients harboring exon 9 mutations frequently do not 
respond to standard dose of IM. A higher dose is usually 
required to control the disease.12,13
The impact of IM in the adjuvant setting was evaluated 
in patients with surgically resected primary GIST. The first 
phase II trial, ASCOSOG Z9000, was conducted in patients 
operated on for a primary GIST with high risk of recurrence 
(size $ 10 cm, ruptured, intraperitoneal hemorrhage, multifo-
cal GIST). The study demonstrated improvement of DFS and 
OS when compared with historical controls.25 The   subsequent 
phase III trial, ACOSOG Z9001, randomized a total of 
708 patients to either 1-year therapy of 400 mg daily of IM 
or placebo with a primary end point of OS and DFS. This trial 
was stopped prematurely because the interim analysis showed 
significant prolongation of DFS. At a median follow-up of 
19.7 months, only 8% of IM-treated patients had recurrence 
compared with 20% of placebo-treated patients. The esti-
mated 1-year DFS was 98% in the IM group compared with 
83% in the placebo group.26 However, the OS was similar 
in both the groups, suggesting that recurrent GIST could be 
successfully rescued using IM. There are two other ongoing 
phase III trials. The EORTC trial 62024 randomizes patients 
with intermediate- or high-risk GIST to 2 years of adjuvant 
IM versus placebo. The Scandinavian Sarcoma Group XVIII 
trial analyzes the effect of IM adjuvant therapy for either 1 
or 3 years. The study completed its accrual, and the results 
are awaited. These data will provide new insights into the 
duration of adjuvant therapy.
Preoperative (neoadjuvant) therapy with IM is an attrac-
tive approach especially if a diminution of the tumor size 
would allow a less extensive and less morbid surgery or if 
the tumor is not resectable. However, data from prospective 
studies are very scant. The results of the phase II RTOG 
0132/ACRIN 6665 were recently published, demonstrat-
ing the feasibility of this approach.27 Fifty-two assessable 
patients, with advanced primary and metastatic/recurrent 
tumors, were treated with 600 mg daily dose of neoadjuvant 
IM. Patients with responding tumors or stable disease were 
recommended surgical resection. Postoperatively, patients 
were further treated with adjuvant IM for 2 years. The median 
length of treatment before surgery was 65 days. The vast 
majority of patients had stable disease prior to surgery. Only 
7% of patients with advanced primary tumor and 4.5% of 
patients with recurrent/metastatic GIST had tumor shrinkage. 
Postoperative complications did not appear to be worsened. 
Two-year progression-free survival was 83% for patients with 
advanced primary GIST and 77% for metastatic/recurrent 
GIST. In another retrospective study, 15 patients with unre-
sectable or locally advanced primary GIST were treated with 
neoadjuvant IM for a median of 9 months. All patients experi-
enced tumor size reduction, with a median shrinkage of 34%. 
Three unresectable patients became resectable, and 7 patients 
had a less extensive surgery than initially planned.28
There is growing evidence that tumor response to IM is bet-
ter assessed by metabolic imaging such as density modifica-
tion on CT scan or Standardized Uptake Values (SUVmax) on 
18FDG-PET scan.29,30 Patients may present with stable disease Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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according to standard Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria but have a demonstrable response 
  according to metabolic imaging. In the Radiation Therapy 
Oncology Group 0132 and American College of Radiology 
Imaging Network (RTOG 0132/ACRIN ) 6665 study, less than 
8% of patients had tumor shrinkage. If tumor size reduction is 
sought, such as in patients presenting with initially unresectable 
tumors, there is some evidence that a longer treatment period 
is needed. However, for marginally resectable patients, the risk 
of progression under lengthy IM therapy must be considered. 
Larger studies with proper controls are needed to assess the 
usefulness of neoadjuvant treatment, especially in patients with 
a primary tumor that is initially resectable.
Mode of action, drug resistance,  
and safety profile of IM
GISTs carry a mutation in the kit gene located on chromosome 
4. The gene encodes a transmembrane protein that serves as 
a receptor for the growth factor stem cell factor (SCF). The 
transmembrane protein has an intracellular domain containing 
the tyrosine kinase enzyme, which, once activated, propagates a 
cascade of activities ultimately causing cell division. The muta-
tion in the kit gene causes uncontrolled activation of the tyrosine 
kinase independently of the growth factor SCF. The activation 
of the tyrosine kinase involves the binding of an adenosine 
triphosphate molecule to the active site of the tyrosine kinase. 
IM is one of the first generations of tyrosine kinase inhibitors 
that works by occupying the active site thereby preventing the 
phosphorylation and activation of the enzyme.31
IM is a 2-phenylaminopyrimidine derivative. Adminis-
tered only orally, it has an oral availability of 98% in patients 
with normal hepatic function. Its absorption is not modified 
by food. It binds primarily to the albumin in plasma. Peak 
plasma levels occur 2–4 hours after oral administration. It is 
metabolized mainly by the cytochrome P450 system in the 
gut wall and liver. Its major metabolite is the N-  demethylated 
piperazine derivate, which is also active. The volume of 
  distribution of IM is not well studied. The elimination half-life 
for IM and its active metabolite averages 18 and 40 hours, 
respectively. IM is mainly excreted by fecal elimination via the 
bile, mostly as metabolites. A quarter of the dose is excreted 
unchanged. Age does not seem to have any significant effect 
on pharmacokinetics. The dosage needs to be adjusted in 
severe hepatic or renal impairment.16,32,33
In a group of phase I, II, and III studies,18,23,34 the most com-
mon toxic effects of IM at 400 mg once daily included nausea, 
vomiting, edema, skin rash, and bone marrow toxicity. These 
side effects were reported to be tolerable. A small percentage of 
patients with large bulky tumors experienced significant tumor 
hemorrhage.21 Hepatotoxicity has also been observed in about 
2%–5% of patients. The toxicity is usually mild and resolves with 
dosage reduction or discontinuation of IM.21,35 Table 1 provides a 
summary of the management of IM toxicity and side effects.
Although tolerable, the impact of these symptoms on the 
quality of life of GIST patients treated with IM has not been 
well studied. The Van Glabbeke group reported extensive data 
on predicting toxicities on 942 GIST patients treated with IM 
using the Common Toxicity Criteria (CTC) grading scale.36 
However, caution should be taken in extrapolating these data 
to patients’ quality of life because they are largely based on 
pathophysiological parameters, and abnormal pathophysio-
logical values do not always translate into poor quality of life. 
There remains a need for a well-designed study that analyzes 
the impact of IM on patients’ quality of life, encompassing 
patients’ satisfaction, acceptability, and adherence.
Although IM is effective against GIST, acquired drug 
resistance remains an important clinical challenge. Sev-
eral different mechanisms of IM have been described.32,37 
Table 1 Management of imatinib mesylate (iM) toxicity16,32,33
interaction with surgery –   imatinib (iM) can be stopped right before surgery and restarted as soon 
as po medication is tolerated
Hepatotoxicity – Monitor LFT initially then monthly x 3 then serially 
– Stop if bilirubin $ 3x iULN or transaminases $ 5x iULN
Bone marrow toxicity –   CBC should be performed weekly for the first month, bi-weekly for the second 
month and every 2–3 months thereafter
Fluid retention –   Superficial retention can be managed with diuretics, other supportive measure or 
dose reduction
Thyroid function 
impairment
– Monitor TSH closely and treat as appropriate 
– A 2-fold increase in levothyroxine is recommended before initiating treatment
Drug interactions – Caution should be taken if patient is taking inhibitor or inducer of de CYP3A4 
–   if large dose of imatinib is prescribed, patient should take no more than 1.3 g a day 
of acetaminophen (imatinib inhibits ACTM glucurodination)
Abbreviations: LFT, liver function test; iULN, institutional upper limit of normal; CBC, complete blood count; TSH, thyroid-stimulating hormone; ACTM, acetaminophen.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Some patients presenting with secondary IM resistance will 
respond to a dose escalation to 400 mg twice a day. If this 
strategy fails, SM can be started. SM is a multi-tyrosine 
kinase inhibitor that has been shown to be active in IM-
resistant or IM-intolerant patients in a phase III trial.19
Patients who progress under IM and SM treatments 
should be included in ongoing clinical trials. Other tyrosine 
kinase inhibitors are now being tested for efficacy in GIST 
treatment. Nilotinib (Tasigna®, Novartis) has been shown to 
be well tolerated and to have clinical activity in IM-resistant 
GIST.38 There are also preclinical studies suggesting an effect 
of the tyrosine kinase inhibitor sorafenib (Nexavar®, Bayer 
Leverkusen, Germany) on GIST.39,40
Combining surgery and IM
Surgery remains the primary treatment for resectable GIST 
and offers the only chance of cure. However, IM has an 
important role to play in patients with increased risk of recur-
rence. Integration of IM with the treatment paradigm in the 
adjuvant setting has significantly decreased the recurrence 
of GIST as demonstrated by ACOSOG Z9001, the phase 
III trial. However, the impact of this approach on long-term 
survival remains unclear. In general, IM treatment can be 
initiated as soon as the patients recover from their surgical 
procedures, especially in patients with significant risk of 
recurrence (tumor size $ 10 cm, $ 5 mitoses per 50 HPF, 
rupture, intraperitoneal hemorrhage, and multifocal GIST). 
The recommended adjuvant therapy is a daily dose of 400 mg 
for 1 year. The benefits of longer duration therapy remain to 
be proven. Neoadjuvant IM should not be routinely used, but 
it should be considered if a downsizing of the tumor would 
allow a less morbid operation. This should be conducted in 
a multidisciplinary setting.
For patients presenting with metastatic or recurrent GIST, the 
exact place of surgery in the IM era remains to be determined. 
Surgery is generally not indicated if a patient presents with gener-
alized disease progression under treatment. In such situation, the 
outcomes appear to be marginal: one study reported no patients free 
of   recurrence at 12 months41 and another reported a median time 
to   progression of 3 months.42 In a patient with diffuse progression, 
medical therapy is more appropriate. IM dose can be increased up to 
400 mg twice a day, and if the disease is resistant to IM, SM can be 
used, which has been shown to be effective in the phase III trial.19
Patients with preoperative response to therapy or at least 
stable disease seem to do better with 2-year progression-free 
survival of 60%–70%.42,43 However, the exact impact of sur-
gery on DFS and OS in this setting is unknown. The prognosis 
for patients undergoing surgery for limited progressive 
disease (progression of only one or few metastases with glob-
ally responding disease) appears to be slightly better than for 
patients with generalized progressive disease.41,42
Conclusion
In the treatment of GIST, surgery and IM therapy are two 
powerful methods that allow us to offer a better prognosis 
to our patients. For primary resectable GIST, the first step 
should be the complete excision of the tumor. Neoadjuvant 
IM therapy can be considered for initially unresectable tumor 
or if a downsizing of the tumor would allow resection with 
decreased surgical morbidity. Adjuvant IM should be given to 
patients at higher risk of recurrence. For patients with meta-
static or recurrent GIST, the treatment is based on IM therapy 
and for resistant or intolerant patients, SM can be used.
Some points remain to be clarified. Notably, the ideal dura-
tion of adjuvant IM after surgery is still unclear. It is difficult to 
determine the exact place of surgery in metastatic or recurrent 
GIST patients. It is also unclear if surgery makes a difference in 
outcomes. A multidisciplinary approach and a close collabora-
tion between the medical oncologist, the gastroenterologist, 
the radiologist, and the surgeon are, therefore, mandatory to 
offer GIST patients the best treatment available.
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